In my 25 years full of passion for the discovery and development of novel antibody therapeutics, led me to be involved in the trajectory of preclinical preparation and design of first-into-man studies of various novel antibody-based medicine, of which ibalizumab has obtained market approval. I have been an inventor of > 20 patent applications across different disease areas. currently focused on designing antibody-based precision medicine accompanied by a relevant companion diagnostic (CDx).
Through my extensive academic collaborations, I have gained extensive experience in molecular and cellular immunology evidenced by my (co)authorship of over 380 publications in international scientific journals in the field of medical biotechnology.

As the CSO at JJP Biologics Warsaw, Poland, I am responsible for our innovative antibody pipeline, which includes humanized antagonist anti-CD89 and its CDx. Furthermore, I am responsible for the development of our high-producing cell lines and CMC development. I have developed our CHOBC® platform and discovered our novel SPOT™ and SLIM™ technologies. Moreover, I developed a modulation toolbox to optimize CQAs. To evaluate the biosimilars in vitro, a complete bio-assay toolbox has been designed to study interaction on living cells. At Polpharma Biologics, we leverage our biological knowledge and platform expertise for other Biotech companies to successfully develop their drugs from idea to commercialization.

#biosimilarmedicine #cdmoservices #NBE #CMCdevelopment #academiccollaboration #precisionmedicine #companiondiagnostic

Specialties: Preclinical development of recombinant novel and biosimilar antibodies. This includes generation and selection of novel antibody therapeutics, the generating high-producing stable cell-lines, CMC development, development of potency, analytical and immunogenicity assays, selection and development of CDx, design of POC studies in animals, design of regulatory toxicology package to support first-into-man studies.